PLYX Stock Forecast: Polaryx Therapeutics, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Polaryx Therapeutics, Inc. hold a median 12-month price target of $7 — +219.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
PLYX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Polaryx Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (74): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Polaryx Therapeutics, Inc. — and when they’d sell — is the membership.
PLYX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLYX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +219.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 July 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $7.00 |
| 9 July 2026 | HC Wainwright & Co. | Initiates | Buy | $7.00 |
| 9 July 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 27 Feb 2026 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLYX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Polaryx Therapeutics, Inc. (PLYX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −12.2×
- Price / sales
- —
- Price / book
- 43.6×
- EV / EBITDA
- −16.0×
Cheaper than 94% of US stocks
Cheaper than 3% of US stocks
Cheaper than 88% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −192.2%
- Return on assets
- −74.4%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PLYX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLYX appears on the weeks it earns a place.
Frequently asked questions about PLYX stock
What is the PLYX stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Polaryx Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PLYX stock a buy right now?
Of the 3 analysts covering Polaryx Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Polaryx Therapeutics, Inc. 25 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PLYX?
As at 1 Aug 2026, Polaryx Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (74 of 100).
Will PLYX stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +219.6% from the last close, and Ticker Nerd's factor model ranks Polaryx Therapeutics, Inc. 25 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PLYX stock forecast for 2030?
No analyst covering Polaryx Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $10 over the next 12 months.
What does Polaryx Therapeutics, Inc. do?
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly treatments for lysosomal storage disorders, a group of rare inherited diseases with significant unmet medical need.
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly treatments for lysosomal storage disorders, a group of rare inherited diseases with significant unmet medical need. The company’s current programs center on non-invasive small molecule therapies and a gene therapy candidate designed to address the underlying biology of these disorders. Its pipeline includes orally available approaches aimed at supporting lysosome function, reducing neuroinflammation, and improving neuronal survival, alongside an intranasal gene therapy candidate intended for use in combination strategies. Polaryx Therapeutics concentrates on rare pediatric and orphan disease markets, with development efforts targeting conditions such as neuronal ceroid lipofuscinosis, Krabbe disease, Sandhoff disease, and Niemann-Pick diseases. Founded in 2014 and headquartered in Paramus, New Jersey, Polaryx Therapeutics plays a specialized role in the biotechnology sector by advancing therapies for underserved rare disease populations.
CEO Mr. Alex Yang J.D., L.L.M. · 2 employees · United States · https://polaryx.com